SecBot SecBot
8-K ·Filed Jul 29, 2026

BLCO

Bausch & Lomb Corp
BULLISH
Impact 6/10
Horizondays Processed3mo ago SEC0001860742-26-000086
8-K Item 2.02: Earnings release
Actionable Insight ▲ Bullish

The raised guidance and accelerating growth in Surgical and Pharmaceuticals are positive signals. Monitor the Q3 earnings call for updates on the enVista Beyond IOL regulatory submission and any impact from tariffs on the supply chain. The adjusted EPS miss is minor and likely overshadowed by the strong top-line beat and guidance raise.

DirectionBullish
Confidencehigh
Horizondays

How the stock moved after the report

BULLISH VIEWSTOCK ABOVE ENTRY AT T+60
Entry
$16.20
T+0 close · Jul 29, 2026 · via day close
Latest settled
+7.59%
T+60 · $17.43
Vs SPY
+2.86%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Jul 29 $16.20entry
  2. T+1 · 4mo ago +4.88%α +3.20% · $16.99
  3. T+5 · 3mo ago +3.46%α −2.07% · $16.76
  4. T+20 · 3mo ago +6.48%α +1.46% · $17.25
  5. T+60 · 26d ago +7.59%α +2.86% · $17.43
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Bausch + Lomb reported Q2 2026 revenue of $1.394B (+9% YoY), slightly above consensus of $1.37B, and adjusted EPS of $0.15, slightly below the $0.16 consensus. The company raised its full-year 2026 revenue guidance to $5.440B-$5.540B and Adjusted EBITDA guidance to $1.025B-$1.075B, citing broad-based growth across all segments, particularly Surgical (+19%) and Pharmaceuticals (+15%). The GAAP net loss narrowed to $14M from $62M a year ago, and operating cash flow improved to $153M from $35M. The stock is likely to move modestly higher on the raised guidance and strong operational momentum, though the adjusted EPS miss tempers the upside.

Key Financial Metrics

EPS
$0.15
est $0.16 · -6.3%
Revenue
$1.4B
est $1.4B · +1.8% · +9.0% YoY
Rating
in line
Guidance
$5.440B - $5.540B
raised

Key Facts

  • Q2 2026 revenue of $1.394B, up 9% YoY (8% constant currency), vs consensus $1.37B
  • Adjusted EPS of $0.15 vs consensus $0.16 (miss by ~6%)
  • GAAP net loss narrowed to $14M from $62M YoY; operating income of $83M vs a loss of $11M
  • Full-year 2026 revenue guidance raised to $5.440B-$5.540B (from $5.420B-$5.520B)
  • Full-year 2026 Adjusted EBITDA guidance raised to $1.025B-$1.075B (from $1.010B-$1.060B)
  • Surgical segment revenue surged 19% (16% constant currency), driven by premium IOLs
  • Pharmaceuticals revenue grew 15% (14% constant currency), led by MIEBO and XIIDRA
  • Operating cash flow improved to $153M from $35M YoY
  • enVista Beyond IOL pivotal study met several co-primary endpoints, though narrowly missed some performance targets

Financial Impact

Revenue beat consensus by ~$24M (1.8%); adjusted EPS missed by $0.01; raised FY guidance by $20M at midpoint

revenueadjusted EBITDAoperating incomecash flow from operations

Risk Factors

  • enVista Beyond IOL narrowly missed some performance targets, potentially delaying or complicating regulatory submission
  • Foreign exchange tailwinds are expected to moderate ($45M vs $50M previously)
  • GAAP net loss persists, though narrowing
  • Tariff policy remains dynamic and could impact 2026 guidance

Market Snapshot

Exchange
NYSE
Sector
Ophthalmic Goods
Analyst Consensus
50% bullish (18 analysts)

Investment Themes

Healthcare & Medical Devices

Documents Analyzed

This report is based on 6 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001860742-26-000086
Document: blco-20260729.htm0001860742-26-000086
Document: 0001860742-26-000086-index-headers.html0001860742-26-000086
Document: 0001860742-26-000086-index.html0001860742-26-000086
Document: 0001860742-26-000086.txt0001860742-26-000086
8-K Data (Synthetic)0001860742-26-000086

Track record

24 reports on BLCO

Performance horizon

3 of 4 bullish or bearish reports moved the stock their way by T+5. Best: +16.89% at T+20 after the Oct 1, 2026 report. 4 of 4 went positive at some point.

Filters
  1. Nov 12, 20264d ago 144 Neutral 2/10 Entry $21.14 Now $20.88 −1.23% settles Nov 19
  2. Nov 3, 202613d ago 144 Neutral 2/10 Entry $20.03 to $21.37 Now $20.88 +4.24% ▲ +6.69% +7.28% vs SPY
  3. Oct 29, 202618d ago 144 Neutral 3/10 Entry $20.00 to $19.99 Now $20.88 +4.40% ▼ −0.05% +2.65% vs SPY
  4. Oct 28, 202619d ago 8-K Neutral 2/10 Entry $20.40 to $19.92 Now $20.88 +2.35% ▼ −2.35% +2.37% vs SPY
  5. Oct 28, 202619d ago 8-K Bullish 6/10 Entry $20.40 to $20.60 Now $20.88 +2.35% ▲ +0.98% +1.69% vs SPY
  6. Oct 13, 20264w ago 8-K Mixed 6/10 Entry $15.81 to $16.93 Now $20.88 +32.07% ▲ +7.08% +8.24% vs SPY
  7. Oct 1, 20266w ago Court Ruling Bullish 4/10 Entry $17.11 to $17.30 Now $20.88 +22.03% ▲ +1.11% −0.05% vs SPY
  8. Sep 28, 20267w ago 144 Neutral 2/10 Entry $16.95 to $17.17 Now $20.88 +23.19% ▲ +1.30% +0.09% vs SPY
  9. Aug 14, 202613w ago 3 / CLUSTER Neutral 2/10 Entry $17.00 to $17.32 Now $20.88 +22.82% ▲ +1.88% +3.07% vs SPY
  10. Aug 14, 202613w ago 3 Neutral 2/10 Entry $17.00 to $17.32 Now $20.88 +22.82% ▲ +1.88% +3.07% vs SPY
Showing 10 of 24

US Market Status

Market Closed · Opens Wed (10h 57m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Jul 29, 2026